|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000084110 |
Summary for HAL |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000084110 | Gene symbol | HAL |
| Gene name | histidine ammonia-lyase | |
| HGNC | 4806 | |
| Entrez ID | 3034 | |
| Gene type | protein_coding | |
| Synonyms | HAL| | |
| UniProtAcc | P42357 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000084110 | HAL | DB00117 | Histidine | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for HAL |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| HAL | 4.32e+03 | -4.30e+00 | 9.53e-01 | -4.51e+00 | 6.38e-06 | 3.77e-05 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for HAL |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for HAL |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| SARC | cg25137372 | chr12:95996281 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 5.49e-01 | 4.24e-01 | 4.45e+00 | 8.54e-06 | 5.41e-05 | 1.25e-01 |
| SARC | cg18817487 | chr12:95996365 | CGI:chr12:95995627-95995897 | promoter | 5.41e-01 | 4.24e-01 | 4.02e+00 | 5.75e-05 | 3.14e-04 | 1.17e-01 |
| CHOL | cg09636302 | chr12:95995705 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 9.57e-01 | 8.12e-01 | 2.80e+00 | 5.09e-03 | 1.32e-02 | 1.45e-01 |
| CHOL | cg27246571 | chr12:95995810 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 9.04e-01 | 7.93e-01 | 2.52e+00 | 1.19e-02 | 2.40e-02 | 1.10e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg09636302 | chr12:95995705 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 6.50e-01 | 8.16e-01 | -2.70e+00 | 6.86e-03 | 9.74e-03 | -1.66e-01 |
| LUAD | cg27246571 | chr12:95995810 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 7.13e-01 | 9.09e-01 | -3.15e+00 | 1.62e-03 | 2.92e-03 | -1.96e-01 |
| HNSC | cg16321323 | chr12:95994811 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 8.17e-01 | 9.46e-01 | -5.63e+00 | 1.78e-08 | 2.83e-07 | -1.29e-01 |
| HNSC | cg18817487 | chr12:95996365 | CGI:chr12:95995627-95995897 | promoter | 1.97e-01 | 3.03e-01 | -3.87e+00 | 1.09e-04 | 2.79e-04 | -1.07e-01 |
| COAD | cg25137372 | chr12:95996281 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 1.78e-01 | 2.78e-01 | -3.71e+00 | 2.10e-04 | 6.36e-04 | -1.00e-01 |
| COAD | cg18817487 | chr12:95996365 | CGI:chr12:95995627-95995897 | promoter | 1.12e-01 | 2.17e-01 | -4.19e+00 | 2.80e-05 | 1.29e-04 | -1.05e-01 |
| COAD | cg21682902 | chr12:95997182 | CGI:chr12:95995627-95995897 | promoter | 6.98e-01 | 8.62e-01 | -2.62e+00 | 8.67e-03 | 1.28e-02 | -1.64e-01 |
| COAD | cg08402850 | chr12:95997474 | CGI:chr12:95995627-95995897 | promoter | 6.09e-01 | 7.15e-01 | -3.34e+00 | 8.27e-04 | 1.92e-03 | -1.06e-01 |
| BLCA | cg22491680 | chr12:95995769 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 6.85e-01 | 8.27e-01 | -3.47e+00 | 5.13e-04 | 1.35e-03 | -1.42e-01 |
| BLCA | cg15438951 | chr12:95995916 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 7.83e-01 | 8.96e-01 | -3.47e+00 | 5.20e-04 | 1.37e-03 | -1.13e-01 |
| ESCA | cg09636302 | chr12:95995705 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 8.71e-01 | 9.76e-01 | -2.67e+00 | 7.58e-03 | 3.54e-02 | -1.05e-01 |
| ESCA | cg22491680 | chr12:95995769 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 6.70e-01 | 8.16e-01 | -2.97e+00 | 2.99e-03 | 3.38e-02 | -1.47e-01 |
| ESCA | cg15438951 | chr12:95995916 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 7.32e-01 | 8.55e-01 | -2.22e+00 | 2.62e-02 | 4.25e-02 | -1.23e-01 |
| ESCA | cg08402850 | chr12:95997474 | CGI:chr12:95995627-95995897 | promoter | 5.06e-01 | 6.30e-01 | -2.05e+00 | 3.99e-02 | 4.66e-02 | -1.24e-01 |
| CHOL | cg09636302 | chr12:95995705 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 8.12e-01 | 5.11e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 3.01e-01 |
| CHOL | cg22491680 | chr12:95995769 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 6.94e-01 | 4.48e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.46e-01 |
| CHOL | cg27246571 | chr12:95995810 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 7.93e-01 | 5.25e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.68e-01 |
| CHOL | cg15438951 | chr12:95995916 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 6.44e-01 | 4.27e-01 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 2.17e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25137372 | chr12:95996281 | CGI:chr12:95995627-95995897 | UTR,promoter,exon,gene body | 3.27e-01 | 4.73e-01 | -8.83e+00 | 1.04e-18 | 5.05e-18 | -1.45e-01 |
| BRCA | cg18817487 | chr12:95996365 | CGI:chr12:95995627-95995897 | promoter | 2.25e-01 | 4.40e-01 | -1.22e+01 | 4.62e-34 | 1.17e-32 | -2.15e-01 |
| LIHC | cg16321323 | chr12:95994811 | CGI:chr12:95995627-95995897 | promoter,gene body,CDS,UTR,exon | 7.14e-01 | 8.95e-01 | -2.27e+00 | 2.32e-02 | 2.71e-02 | -1.80e-01 |
Top |
Exon skipping events with PSI in TCGA for HAL |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for HAL |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LIHC | HAL-005 | chr12_95975486_- | 4.33e-01 | 3.45e-01 | 2.04e+00 | 4.15e-02 | 4.82e-02 | 8.79e-02 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for HAL |
| TFs related to HAL. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| HAL related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for HAL |
| RBPs related to ES in HAL. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| HAL related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000084110 | AC006449.2,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
| ENSG00000084110 | LINC02783,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
| ENSG00000084110 | MIR99AHG,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
| ENSG00000084110 | CRYZL2P-SEC16B,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
| ENSG00000084110 | SNHG29,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
| ENSG00000084110 | DLGAP1-AS1,hsa-mir-149,HAL | Female-specific ceRNA | TCGA-KICH |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35584669 | chr12:88234571:G:T | - | 0.122892087024673 | 0.0210087103241269 | HNSC | Female-baised eQTL |
| rs73374441 | chr12:100221446:C:G | - | 0.220262506527818 | 0.039399747705359 | LIHC | Female-baised eQTL |
| rs12427334 | chr12:93625926:T:G | - | 0.0847510539474587 | 0.0155131248737164 | LUAD | Female-baised eQTL |
| rs12296509 | chr12:91845017:T:G | - | 0.0720025119523119 | 0.0410318665742033 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000084110 |
| CpG Site: cg22491680 | |
| Position to Gene: gene,CDS,UTR,promoter,exon | |
| Male Effect: - | |
| Female Effect: -0.466915008783097 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg22491680 | chr12:95995769 | gene,CDS,UTR,promoter,exon | -0.466915008783097 | 7.19874735421261e-08 | -0.38778333433832085 | 1.4106190471743814e-10 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of HAL |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000084110 | HAL | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| ENSG00000084110 | HAL | C0220992 | Histidinemia | 1 | CTD_human |
